donepezil has been researched along with Age-Related Memory Disorders in 137 studies
Donepezil: An indan and piperidine derivative that acts as a selective and reversible inhibitor of ACETYLCHOLINESTERASE. Donepezil is highly selective for the central nervous system and is used in the management of mild to moderate DEMENTIA in ALZHEIMER DISEASE.
donepezil : A racemate comprising equimolar amounts of (R)- and (S)-donepezil. A centrally acting reversible acetylcholinesterase inhibitor, its main therapeutic use is in the treatment of Alzheimer's disease where it is used to increase cortical acetylcholine.
2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one : A member of the class of indanones that is 5,6-dimethoxyindan-1-one which is substituted at position 2 by an (N-benzylpiperidin-4-yl)methyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Twenty-three epilepsy patients with subjective memory difficulty were randomized to either 3 months of donepezil (10 mg/day) or 3 months of placebo treatment, and then crossed over to the other treatment arm." | 9.12 | A randomized, double-blind, placebo-controlled trial of donepezil to improve memory in epilepsy. ( Choi, H; Hamberger, MJ; Hirsch, LJ; Palmese, CA; Scarmeas, N; Weintraub, D, 2007) |
| "This study investigated the efficacy of the cholinesterase agent donepezil in the treatment of menopause-related cognitive loss." | 9.12 | A double-blind, placebo-controlled trial of donepezil for the treatment of menopause-related cognitive loss. ( Devi, G; Khosrowshahi, L; Laakso, UK; Massimi, S; Schultz, S, 2007) |
| "Our results indicate that donepezil may reverse obesity-related central inflammation and oxidative damage and improve memory deficit in HFD-fed mice." | 7.91 | Donepezil Attenuates Obesity-Associated Oxidative Stress and Central Inflammation and Improves Memory Deficit in Mice Fed a High-Fat Diet. ( Chen, J; Fu, X; Jiang, L; Ren, H; Su, L; Wang, C; Wang, Y, 2019) |
| " In this study, we tested the effects of a synthesized juxtaposition (named SCR1693) composed of an acetylcholinesterase inhibitor (AChEI) and a calcium channel blocker (CCB) on the hyperhomocysteinemia (HHcy)-induced AD rat model, and found that SCR1693 remarkably improved the HHcy-induced memory deficits and preserved dendrite morphologies as well as spine density by upregulating synapse-associated proteins PSD95 and synapsin-1." | 7.80 | Novel multipotent AChEI-CCB attenuates hyperhomocysteinemia-induced memory deficits and Neuropathologies in rats. ( Chen, R; Hu, J; Liu, R; Liu, X; Tian, Q; Wang, JZ; Wang, P; Wang, Q; Wang, XC; Xia, Y; Zeng, K, 2014) |
| " In the present study, we reported that donepezil, a cholinesterase inhibitor, improved transient global cerebral ischemia-induced spatial memory impairment in gerbils." | 7.78 | Donepezil attenuates hippocampal neuronal damage and cognitive deficits after global cerebral ischemia in gerbils. ( Cai, J; Cao, Y; Chen, T; Guo, F; Mao, X; Min, D; Shaw, C; Wang, L; Wu, K; Xie, N; Zhu, S, 2012) |
| " Furthermore, we evaluated the effect of anti-dementia drugs memantine, a NMDA antagonist, and donepezil, a cholinesterase inhibitor, on OKA ICV induced memory impairment." | 7.76 | Okadaic acid (ICV) induced memory impairment in rats: a suitable experimental model to test anti-dementia activity. ( Kamat, PK; Nath, C; Saxena, G; Shukla, R; Tota, S, 2010) |
| "All bipolar disordered patients in a private practice setting treated with donepezil for memory problems were analyzed." | 7.74 | Is donepezil useful for improving cognitive dysfunction in bipolar disorder? ( Kelly, T, 2008) |
| " Therefore, the present study was designed to investigate the influence of antidementia drugs, tacrine and donepezil, on biochemical markers of oxidative stress, glutathione (GSH) and malondialdehyde (MDA), and acetylcholinesterase activity in the brain in a streptozotocin-induced experimental model of dementia in mice." | 7.74 | Effect of donepezil and tacrine on oxidative stress in intracerebral streptozotocin-induced model of dementia in mice. ( Agrawal, R; Nath, C; Saxena, G; Singh, SP, 2008) |
| "Donepezil 10 mg daily was compared to placebo to treat memory impairment." | 6.76 | Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis. ( Benedict, RH; Christodoulou, C; Goodman, A; He, D; Krupp, LB; Melville, P; Muenz, LR; Pai, LY; Rizvi, S; Scherl, WF; Schwid, SR; Weinstock-Guttman, B; Westervelt, HJ; Wishart, H, 2011) |
| "Ferulic acid (FA) acts as a powerful antioxidant against various age-related diseases." | 5.43 | Ferulic acid ameliorates memory impairment in d-galactose-induced aging mouse model. ( Gao, J; Gao, W; Huo, L; Qu, Z; Yang, H; Zhang, J, 2016) |
| "Twenty-three epilepsy patients with subjective memory difficulty were randomized to either 3 months of donepezil (10 mg/day) or 3 months of placebo treatment, and then crossed over to the other treatment arm." | 5.12 | A randomized, double-blind, placebo-controlled trial of donepezil to improve memory in epilepsy. ( Choi, H; Hamberger, MJ; Hirsch, LJ; Palmese, CA; Scarmeas, N; Weintraub, D, 2007) |
| "This study investigated the efficacy of the cholinesterase agent donepezil in the treatment of menopause-related cognitive loss." | 5.12 | A double-blind, placebo-controlled trial of donepezil for the treatment of menopause-related cognitive loss. ( Devi, G; Khosrowshahi, L; Laakso, UK; Massimi, S; Schultz, S, 2007) |
| "To evaluate the efficacy and safety of donepezil, an acetylcholinesterase inhibitor, as a treatment for cognitive impairment and dementia in patients with Parkinson' s disease (PD)." | 5.11 | Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease. ( Brandt, J; Grill, S; Leroi, I; Lyketsos, CG; Marsh, L; Reich, SG; Thompson, R, 2004) |
| "(1) Donepezil can reduce memory loss, dry mouth, and constipation in nongeriatric affective patients, but may trigger mania; and (2) long-term follow-up will reveal the predictive value for dementia of donepezil's memory restoration in nongeriatric subjects." | 5.09 | Donepezil for psychotropic-induced memory loss. ( Comas-Díaz, L; Jacobsen, FM, 1999) |
| "This review discusses the laboratory and clinical research supporting the rationale for the efficacy of donepezil (Aricept USA) in enhancing cognition in autism, Alzheimer disease, Down syndrome, traumatic brain injury, Attention Deficit Hyperactivity Disorder (ADHD), and schizophrenia." | 4.84 | Relevance of donepezil in enhancing learning and memory in special populations: a review of the literature. ( Valdovinos, MG; Williams, DC; Yoo, JH, 2007) |
| "Our results indicate that donepezil may reverse obesity-related central inflammation and oxidative damage and improve memory deficit in HFD-fed mice." | 3.91 | Donepezil Attenuates Obesity-Associated Oxidative Stress and Central Inflammation and Improves Memory Deficit in Mice Fed a High-Fat Diet. ( Chen, J; Fu, X; Jiang, L; Ren, H; Su, L; Wang, C; Wang, Y, 2019) |
| " In this study, we tested the effects of a synthesized juxtaposition (named SCR1693) composed of an acetylcholinesterase inhibitor (AChEI) and a calcium channel blocker (CCB) on the hyperhomocysteinemia (HHcy)-induced AD rat model, and found that SCR1693 remarkably improved the HHcy-induced memory deficits and preserved dendrite morphologies as well as spine density by upregulating synapse-associated proteins PSD95 and synapsin-1." | 3.80 | Novel multipotent AChEI-CCB attenuates hyperhomocysteinemia-induced memory deficits and Neuropathologies in rats. ( Chen, R; Hu, J; Liu, R; Liu, X; Tian, Q; Wang, JZ; Wang, P; Wang, Q; Wang, XC; Xia, Y; Zeng, K, 2014) |
| " In the present study, we reported that donepezil, a cholinesterase inhibitor, improved transient global cerebral ischemia-induced spatial memory impairment in gerbils." | 3.78 | Donepezil attenuates hippocampal neuronal damage and cognitive deficits after global cerebral ischemia in gerbils. ( Cai, J; Cao, Y; Chen, T; Guo, F; Mao, X; Min, D; Shaw, C; Wang, L; Wu, K; Xie, N; Zhu, S, 2012) |
| " Furthermore, we evaluated the effect of anti-dementia drugs memantine, a NMDA antagonist, and donepezil, a cholinesterase inhibitor, on OKA ICV induced memory impairment." | 3.76 | Okadaic acid (ICV) induced memory impairment in rats: a suitable experimental model to test anti-dementia activity. ( Kamat, PK; Nath, C; Saxena, G; Shukla, R; Tota, S, 2010) |
| " Therefore, the present study was designed to investigate the influence of antidementia drugs, tacrine and donepezil, on biochemical markers of oxidative stress, glutathione (GSH) and malondialdehyde (MDA), and acetylcholinesterase activity in the brain in a streptozotocin-induced experimental model of dementia in mice." | 3.74 | Effect of donepezil and tacrine on oxidative stress in intracerebral streptozotocin-induced model of dementia in mice. ( Agrawal, R; Nath, C; Saxena, G; Singh, SP, 2008) |
| "All bipolar disordered patients in a private practice setting treated with donepezil for memory problems were analyzed." | 3.74 | Is donepezil useful for improving cognitive dysfunction in bipolar disorder? ( Kelly, T, 2008) |
| "Cotreatment with donepezil (10 mg) significantly ameliorated scopolamine-induced impairment at the 2-h time point (Cohen's d = 0." | 2.78 | Effect of cholinergic neurotransmission modulation on visual spatial paired associate learning in healthy human adults. ( Harel, BT; Maruff, P; Pietrzak, RH; Snyder, PJ, 2013) |
| "Donepezil 10 mg daily was compared to placebo to treat memory impairment." | 2.76 | Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis. ( Benedict, RH; Christodoulou, C; Goodman, A; He, D; Krupp, LB; Melville, P; Muenz, LR; Pai, LY; Rizvi, S; Scherl, WF; Schwid, SR; Weinstock-Guttman, B; Westervelt, HJ; Wishart, H, 2011) |
| " Tolerability can be increased by use of flexible dosing and efficacy is likely to be enhanced by increasing the length of the trial from six to 12 months and by enriching the sample with subjects more likely to decline during the trial." | 2.73 | Key lessons learned from short-term treatment trials of cholinesterase inhibitors for amnestic MCI. ( Correia, S; Richardson, S; Salloway, S, 2008) |
| " Physiological tolerance may occur with chronic donepezil treatment and may increase AChE levels; this may be why short-term studies have shown the benefit of AChE inhibitor use in nondemented participants whereas chronic use has failed to enhance cognition." | 2.73 | Acetylcholinesterase inhibitor in combination with cognitive training in older adults. ( Ashford, JW; Friedman, L; Hoblyn, J; Kraemer, HC; Mumenthaler, MS; Noda, A; Yesavage, JA, 2008) |
| "Donepezil was associated with significantly more adverse effects compared with placebo, mostly gastrointestinal." | 2.43 | Donepezil for mild cognitive impairment. ( Birks, J; Flicker, L, 2006) |
| "Treatment approaches to memory loss typically use Alzheimer's dementia as the template, and are discussed in this report." | 2.41 | Approaches to memory loss in neuropsychiatric disorders. ( Devi, G; Silver, J, 2000) |
| "Isofraxidin or donepezil was administered for 44 days, once per day." | 1.72 | Protective effects of isofraxidin against scopolamine-induced cognitive and memory impairments in mice involve modulation of the BDNF-CREB-ERK signaling pathway. ( Gu, J; Li, F; Lian, B; Wu, X; Yu, M; Zhang, C; Zhao, AZ; Zou, Z, 2022) |
| "MO reversed Sco-induced memory deficits and brain oxidative stress, along with cholinesterase inhibitory effects, which is an important mechanism in the anti-amnesia effect." | 1.56 | Cognitive Facilitation and Antioxidant Effects of an Essential Oil Mix on Scopolamine-Induced Amnesia in Rats: Molecular Modeling of In Vitro and In Vivo Approaches. ( Boiangiu, RS; Brinza, I; Cioanca, O; Erdogan Orhan, I; Eren, G; Ertas, H; Gündüz, E; Hancianu, M; Hritcu, L, 2020) |
| "Donepezil pretreatment prevented working memory impairment and the decrease of the protein levels of ChAT induced by anesthesia/surgery." | 1.48 | Central cholinergic system mediates working memory deficit induced by anesthesia/surgery in adult mice. ( Chen, X; Gu, X; Huang, L; Jiang, X; Su, D; Tian, J; Tian, W; Yu, W; Zhang, X, 2018) |
| " Further drug-like property analysis demonstrated that the optimized compound, 8d (WI-1758), had liver microsomal metabolic stability, was well tolerated (>2000 mg/kg), and had a rational pharmacokinetic profile, as well as an oral bioavailability of 14." | 1.48 | Design, Synthesis, and Evaluation of Orally Bioavailable Quinoline-Indole Derivatives as Innovative Multitarget-Directed Ligands: Promotion of Cell Proliferation in the Adult Murine Hippocampus for the Treatment of Alzheimer's Disease. ( Chan, ASC; Feng, X; Hu, J; Huang, L; Li, X; Wang, Z; Yang, X, 2018) |
| "The effects of AD-35 on cognitive impairments and neuroinflammatory changes caused by intracerebroventricular injection of Aβ25-35 were studied in rats." | 1.46 | Multifunctional Compound AD-35 Improves Cognitive Impairment and Attenuates the Production of TNF-α and IL-1β in an Aβ25-35-induced Rat Model of Alzheimer's Disease. ( Cai, J; Feng, N; Feng, R; Gong, Y; Li, J; Li, L; Liu, L; Peng, Y; Wang, L; Wang, X; Xu, S; Zhao, X, 2017) |
| "Rolipram treatment significantly attenuated STZ induced and age related memory deficits, biochemical and histopathological alterations." | 1.46 | Inhibitor of Phosphodiestearse-4 improves memory deficits, oxidative stress, neuroinflammation and neuropathological alterations in mouse models of dementia of Alzheimer's Type. ( Kumar, A; Singh, N, 2017) |
| "Ferulic acid (FA) acts as a powerful antioxidant against various age-related diseases." | 1.43 | Ferulic acid ameliorates memory impairment in d-galactose-induced aging mouse model. ( Gao, J; Gao, W; Huo, L; Qu, Z; Yang, H; Zhang, J, 2016) |
| "Furthermore, the effects of UW-MD-71 on memory deficits induced by the non-competitive N-methyl-d-aspartate (NMDA) antagonist dizocilpine (DIZ) were tested." | 1.43 | The dual-acting H3 receptor antagonist and AChE inhibitor UW-MD-71 dose-dependently enhances memory retrieval and reverses dizocilpine-induced memory impairment in rats. ( Darras, FH; Decker, M; Khan, N; Nurulain, SM; Saad, A; Sadek, B, 2016) |
| "Rosmarinic acid (RA) is a natural phenol that exerts different biological activities, such as antioxidant activity and neuroprotective effects." | 1.42 | Ameliorative effect of rosmarinic acid on scopolamine-induced memory impairment in rats. ( Hasanein, P; Mahtaj, AK, 2015) |
| "Donepezil is a well-known anti-dementia agent that increases acetylcholine levels through inhibition of acetylcholinesterase." | 1.40 | Donepezil inhibits the amyloid-beta oligomer-induced microglial activation in vitro and in vivo. ( Choi, JG; Hur, J; Kim, AJ; Kim, HG; Lee, KT; Moon, M; Oh, MS; Park, G, 2014) |
| "Alzheimer's disease is characterized by a progressive decline in cognitive function and involves β-amyloid (Aβ) in its pathogenesis." | 1.39 | Characterization of cognitive deficits in a transgenic mouse model of Alzheimer's disease and effects of donepezil and memantine. ( Matsuoka, N; Nagakura, A; Shitaka, Y; Yarimizu, J, 2013) |
| "Hypersexuality in Alzheimer's disease (AD) has been rarely investigated." | 1.35 | Effect of citalopram in treating hypersexuality in an Alzheimer's disease case. ( Bruno, G; Lenzi, GL; Talarico, G; Tosto, G, 2008) |
| "Dementia was induced in Swiss albino mice by administration of Celecoxib (100 mg kg(-1) orally, daily for 9 days) or Streptozotocin (3 mg kg(-1) administered intracerebroventricularly on 1st and 3rd day) and the cognitive behaviors of Swiss albino mice were assessed using Morris water maze test." | 1.35 | Exploitation of HIV protease inhibitor Indinavir as a memory restorative agent in experimental dementia. ( Jaggi, AS; Sharma, B; Singh, M; Singh, N, 2008) |
| "Donepezil is an acetylcholinesterase inhibitor that is used to treat Alzheimer's disease." | 1.35 | Neuroprotective and antiamnesic effect of donepezil, a nicotinic acetylcholine-receptor activator, on rats with concussive mild traumatic brain injury. ( Abe, T; Fujiki, M; Hikawa, T; Ishii, K; Kamida, T; Kobayashi, H; Kubo, T; Sugita, K, 2008) |
| " The present study was designed to investigate the influence of chronic administration of donepezil (cholinesterase inhibitor, 1 and 3 mg/kg) and lercanidipine (L-type calcium channel blocker, 0." | 1.33 | Effect of donepezil and lercanidipine on memory impairment induced by intracerebroventricular streptozotocin in rats. ( Kaul, C; Ramarao, P; Sonkusare, S; Srinivasan, K, 2005) |
| "Donepezil treatment improved average task accuracy, but intersubject variability prohibited statistical significance." | 1.32 | Donepezil-induced improvement in delayed matching accuracy by young and old rhesus monkeys. ( Buccafusco, JJ; Terry, AV, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (2.19) | 18.2507 |
| 2000's | 49 (35.77) | 29.6817 |
| 2010's | 70 (51.09) | 24.3611 |
| 2020's | 15 (10.95) | 2.80 |
| Authors | Studies |
|---|---|
| Sang, Z | 3 |
| Qiang, X | 1 |
| Li, Y | 1 |
| Yuan, W | 1 |
| Liu, Q | 1 |
| Shi, Y | 1 |
| Ang, W | 1 |
| Luo, Y | 1 |
| Tan, Z | 2 |
| Deng, Y | 1 |
| Pan, W | 1 |
| Wang, K | 2 |
| Ma, Q | 1 |
| Yu, L | 1 |
| Yang, Y | 1 |
| Bai, P | 2 |
| Leng, C | 1 |
| Xu, Q | 1 |
| Li, X | 2 |
| Liu, W | 1 |
| Wang, Z | 1 |
| Hu, J | 2 |
| Yang, X | 1 |
| Feng, X | 1 |
| Huang, L | 2 |
| Chan, ASC | 1 |
| Gurjar, AS | 1 |
| Darekar, MN | 1 |
| Yeong, KY | 1 |
| Ooi, L | 1 |
| Zhang, P | 1 |
| Shi, J | 1 |
| Cheng, X | 1 |
| Zhang, Q | 1 |
| Zheng, C | 1 |
| Cheng, Y | 1 |
| Yang, J | 1 |
| Lu, X | 1 |
| Malek, R | 1 |
| Arribas, RL | 1 |
| Palomino-Antolin, A | 1 |
| Totoson, P | 1 |
| Demougeot, C | 1 |
| Kobrlova, T | 1 |
| Soukup, O | 1 |
| Iriepa, I | 1 |
| Moraleda, I | 1 |
| Diez-Iriepa, D | 1 |
| Godyń, J | 1 |
| Panek, D | 1 |
| Malawska, B | 1 |
| Głuch-Lutwin, M | 1 |
| Mordyl, B | 1 |
| Siwek, A | 1 |
| Chabchoub, F | 1 |
| Marco-Contelles, J | 1 |
| Kiec-Kononowicz, K | 1 |
| Egea, J | 1 |
| de Los Ríos, C | 1 |
| Ismaili, L | 1 |
| Oliveira, AWC | 1 |
| Pacheco, JVN | 1 |
| Costa, CS | 1 |
| Aquino, J | 1 |
| Maior, RS | 1 |
| Barros, M | 1 |
| Huang, LP | 1 |
| Zhong, XQ | 1 |
| Zhou, XY | 1 |
| Deng, MQ | 1 |
| Wu, MJ | 1 |
| Deng, MZ | 1 |
| Lian, B | 1 |
| Gu, J | 1 |
| Zhang, C | 2 |
| Zou, Z | 1 |
| Yu, M | 1 |
| Li, F | 1 |
| Wu, X | 1 |
| Zhao, AZ | 1 |
| Anoush, M | 2 |
| Tayebi, N | 1 |
| Bijani, S | 2 |
| Ebrahimi, M | 1 |
| Yazdinezhad, AR | 1 |
| Hosseini, MJ | 2 |
| Dos Santos, A | 4 |
| Teixeira, FC | 4 |
| da Silva, DS | 3 |
| Veleda, TA | 3 |
| de Mello, JE | 4 |
| Luduvico, KP | 4 |
| Tavares, RG | 3 |
| Stefanello, FM | 3 |
| Cunico, W | 4 |
| Spanevello, RM | 3 |
| de Campos, DL | 2 |
| Queiroz, LY | 2 |
| Fontes-Junior, EA | 2 |
| Pinheiro, BG | 2 |
| da Silva, JKR | 2 |
| Maia, CSF | 2 |
| Maia, JGS | 2 |
| de Souza Cardoso, J | 1 |
| de Aguiar, MSS | 1 |
| Vizzotto, M | 1 |
| Stefanello, F | 1 |
| Spanevello, R | 1 |
| Moslemifar, F | 1 |
| Jahanpour, F | 1 |
| Kalantari-Hesari, A | 1 |
| Adeniyi, IA | 1 |
| Oregbesan, PO | 1 |
| Adesanya, A | 1 |
| Olubori, MA | 1 |
| Olayinka, GS | 1 |
| Ajayi, AM | 1 |
| Onasanwo, SA | 1 |
| Pooladgar, P | 1 |
| Sakhabakhsh, M | 1 |
| Soleiman-Meigooni, S | 1 |
| Taghva, A | 1 |
| Nasiri, M | 1 |
| Darazam, IA | 1 |
| Jiang, L | 1 |
| Wang, Y | 1 |
| Su, L | 1 |
| Ren, H | 1 |
| Wang, C | 1 |
| Chen, J | 2 |
| Fu, X | 1 |
| Boiangiu, RS | 1 |
| Brinza, I | 1 |
| Hancianu, M | 1 |
| Erdogan Orhan, I | 1 |
| Eren, G | 1 |
| Gündüz, E | 1 |
| Ertas, H | 1 |
| Hritcu, L | 1 |
| Cioanca, O | 1 |
| Gomaa, AA | 1 |
| Makboul, RM | 1 |
| El-Mokhtar, MA | 1 |
| Abdel-Rahman, EA | 1 |
| Ahmed, EA | 1 |
| Nicola, MA | 1 |
| Dutta, LCB | 1 |
| Sarkar, CP | 1 |
| Andrade, C | 1 |
| Ademosun, AO | 1 |
| Adebayo, AA | 1 |
| Popoola, TV | 1 |
| Oboh, G | 2 |
| Knakker, B | 1 |
| Oláh, V | 1 |
| Trunk, A | 1 |
| Lendvai, B | 1 |
| Lévay, G | 1 |
| Hernádi, I | 1 |
| Nisha, SA | 1 |
| Devi, KP | 1 |
| Havolli, E | 1 |
| Hill, MD | 1 |
| Godley, A | 1 |
| Goetghebeur, PJ | 1 |
| Rahman, A | 1 |
| Lamberty, Y | 1 |
| Schenker, E | 1 |
| Cella, M | 1 |
| Languille, S | 1 |
| Bordet, R | 1 |
| Richardson, J | 1 |
| Pifferi, F | 1 |
| Aujard, F | 1 |
| Bellman, S | 1 |
| Bretin, S | 1 |
| Krazem, A | 1 |
| Henkous, N | 1 |
| Froger-Colleaux, C | 1 |
| Mocaer, E | 1 |
| Louis, C | 2 |
| Perdaems, N | 1 |
| Marighetto, A | 1 |
| Beracochea, D | 2 |
| Watremez, W | 1 |
| Jackson, J | 1 |
| Almari, B | 1 |
| McLean, SL | 1 |
| Grayson, B | 1 |
| Neill, JC | 1 |
| Fischer, N | 1 |
| Allouche, A | 1 |
| Koziel, V | 1 |
| Pillot, T | 1 |
| Harte, MK | 1 |
| Kaundal, M | 1 |
| Deshmukh, R | 1 |
| Akhtar, M | 1 |
| Zhang, X | 1 |
| Jiang, X | 1 |
| Tian, W | 1 |
| Chen, X | 1 |
| Gu, X | 1 |
| Yu, W | 1 |
| Tian, J | 1 |
| Su, D | 2 |
| Nirogi, R | 1 |
| Abraham, R | 1 |
| Benade, V | 1 |
| Medapati, RB | 1 |
| Jayarajan, P | 1 |
| Bhyrapuneni, G | 1 |
| Muddana, N | 1 |
| Mekala, VR | 1 |
| Subramanian, R | 1 |
| Shinde, A | 1 |
| Kambhampati, R | 1 |
| Jasti, V | 1 |
| Llopis, K | 1 |
| Danober, L | 1 |
| Panayi, F | 1 |
| Lestage, P | 1 |
| Omorogbe, O | 1 |
| Zhang, J | 2 |
| Wang, J | 1 |
| Zhou, GS | 1 |
| Tan, YJ | 1 |
| Tao, HJ | 1 |
| Chen, JQ | 1 |
| Pu, ZJ | 1 |
| Ma, JY | 1 |
| She, W | 1 |
| Kang, A | 1 |
| Zhu, Y | 1 |
| Liu, P | 1 |
| Zhu, ZH | 1 |
| Shi, XQ | 1 |
| Tang, YP | 1 |
| Duan, JA | 1 |
| Philpot, RM | 1 |
| Ficken, M | 1 |
| Johns, BE | 1 |
| Engberg, ME | 1 |
| Wecker, L | 1 |
| Harel, BT | 1 |
| Pietrzak, RH | 2 |
| Snyder, PJ | 2 |
| Maruff, P | 2 |
| Kadowaki Horita, T | 1 |
| Kobayashi, M | 1 |
| Mori, A | 1 |
| Jenner, P | 1 |
| Kanda, T | 1 |
| Mishra, N | 1 |
| Sasmal, D | 1 |
| Singh, KK | 1 |
| Kim, HG | 1 |
| Moon, M | 1 |
| Choi, JG | 1 |
| Park, G | 1 |
| Kim, AJ | 1 |
| Hur, J | 2 |
| Lee, KT | 1 |
| Oh, MS | 1 |
| Umukoro, S | 1 |
| Adewole, FA | 1 |
| Eduviere, AT | 1 |
| Aderibigbe, AO | 1 |
| Onwuchekwa, C | 1 |
| He, D | 3 |
| Zhang, Y | 1 |
| Dong, S | 1 |
| Wang, D | 1 |
| Gao, X | 1 |
| Zhou, H | 2 |
| Akaishi, T | 1 |
| Xia, Y | 1 |
| Liu, R | 1 |
| Chen, R | 1 |
| Tian, Q | 1 |
| Zeng, K | 1 |
| Liu, X | 1 |
| Wang, Q | 1 |
| Wang, P | 1 |
| Wang, XC | 1 |
| Wang, JZ | 1 |
| Weon, JB | 1 |
| Lee, J | 1 |
| Eom, MR | 1 |
| Jung, YS | 1 |
| Ma, CJ | 1 |
| Meunier, J | 1 |
| Borjini, N | 1 |
| Gillis, C | 1 |
| Villard, V | 1 |
| Maurice, T | 2 |
| Hasanein, P | 2 |
| Mahtaj, AK | 1 |
| Shi, SH | 1 |
| Zhao, X | 2 |
| Liu, AJ | 1 |
| Liu, B | 1 |
| Li, H | 1 |
| Wu, B | 2 |
| Bi, KS | 1 |
| Jia, Y | 1 |
| Hashimoto, T | 1 |
| Hatayama, Y | 1 |
| Nakamichi, K | 1 |
| Yoshida, N | 1 |
| Guo, HB | 1 |
| Cheng, YF | 1 |
| Wu, JG | 1 |
| Wang, CM | 1 |
| Wang, HT | 1 |
| Qiu, ZK | 1 |
| Xu, JP | 1 |
| Yu, TS | 1 |
| Kim, A | 1 |
| Kernie, SG | 1 |
| Puri, V | 1 |
| Wang, X | 3 |
| Vardigan, JD | 1 |
| Kuduk, SD | 1 |
| Uslaner, JM | 1 |
| Gong, YX | 1 |
| Zhu, QF | 1 |
| Zhong, JQ | 1 |
| Liu, LF | 1 |
| Li, XF | 1 |
| Zheng, XH | 1 |
| Luo, HY | 1 |
| Zhao, XY | 1 |
| Patil, S | 2 |
| Tawari, S | 2 |
| Mundhada, D | 2 |
| Nadeem, S | 1 |
| Khan, N | 1 |
| Saad, A | 1 |
| Nurulain, SM | 1 |
| Darras, FH | 1 |
| Decker, M | 1 |
| Sadek, B | 1 |
| Yang, H | 1 |
| Qu, Z | 1 |
| Huo, L | 1 |
| Gao, J | 1 |
| Gao, W | 1 |
| Seifi, R | 1 |
| Hajinezhad, MR | 1 |
| Emamjomeh, A | 1 |
| Gawel, K | 1 |
| Labuz, K | 1 |
| Gibula-Bruzda, E | 1 |
| Jenda, M | 1 |
| Marszalek-Grabska, M | 1 |
| Filarowska, J | 1 |
| Silberring, J | 1 |
| Kotlinska, JH | 1 |
| Zhang, ZX | 1 |
| Zhao, RP | 1 |
| Wang, DS | 1 |
| Wang, AN | 1 |
| Akinyemi, AJ | 1 |
| Oyeleye, SI | 1 |
| Ogunsuyi, O | 1 |
| Kumar, A | 1 |
| Singh, N | 2 |
| Li, L | 1 |
| Xu, S | 1 |
| Liu, L | 1 |
| Feng, R | 1 |
| Gong, Y | 1 |
| Li, J | 1 |
| Cai, J | 2 |
| Feng, N | 1 |
| Wang, L | 2 |
| Peng, Y | 1 |
| Thomas, E | 1 |
| Jackson, CE | 1 |
| Bednar, M | 1 |
| Tosto, G | 1 |
| Talarico, G | 1 |
| Lenzi, GL | 1 |
| Bruno, G | 1 |
| Yesavage, JA | 1 |
| Friedman, L | 1 |
| Ashford, JW | 1 |
| Kraemer, HC | 1 |
| Mumenthaler, MS | 1 |
| Noda, A | 1 |
| Hoblyn, J | 1 |
| Benetti, F | 1 |
| Mello, PB | 1 |
| Bonini, JS | 1 |
| Monteiro, S | 1 |
| Cammarota, M | 1 |
| Izquierdo, I | 1 |
| Rao, NP | 1 |
| Palaniyappan, P | 1 |
| Chandur, J | 1 |
| Venkatasubramanian, G | 1 |
| Gangadhar, BN | 1 |
| Riedel, G | 1 |
| Kang, SH | 1 |
| Choi, DY | 1 |
| Platt, B | 1 |
| Kamat, PK | 3 |
| Tota, S | 3 |
| Saxena, G | 3 |
| Shukla, R | 4 |
| Nath, C | 6 |
| Le Cozannet, R | 1 |
| Fone, KC | 1 |
| Moran, PM | 1 |
| Agrawal, R | 2 |
| Tyagi, E | 1 |
| Bhutada, P | 2 |
| Mundhada, Y | 1 |
| Bansod, K | 1 |
| Dixit, P | 1 |
| Umathe, S | 1 |
| Krupp, LB | 1 |
| Christodoulou, C | 1 |
| Melville, P | 1 |
| Scherl, WF | 1 |
| Pai, LY | 1 |
| Muenz, LR | 1 |
| Benedict, RH | 1 |
| Goodman, A | 1 |
| Rizvi, S | 1 |
| Schwid, SR | 1 |
| Weinstock-Guttman, B | 1 |
| Westervelt, HJ | 1 |
| Wishart, H | 1 |
| Araujo, JA | 1 |
| Greig, NH | 1 |
| Ingram, DK | 1 |
| Sandin, J | 1 |
| de Rivera, C | 1 |
| Milgram, NW | 1 |
| Patro, IK | 1 |
| de Bruin, NM | 1 |
| Prickaerts, J | 1 |
| van Loevezijn, A | 1 |
| Venhorst, J | 1 |
| de Groote, L | 1 |
| Houba, P | 1 |
| Reneerkens, O | 1 |
| Akkerman, S | 1 |
| Kruse, CG | 1 |
| Jeon, S | 1 |
| Bose, S | 1 |
| Jun, K | 1 |
| Kim, YK | 1 |
| Cho, KS | 1 |
| Koo, BS | 1 |
| Browne, G | 1 |
| Berry, E | 1 |
| Kapur, N | 1 |
| Hodges, S | 1 |
| Smyth, G | 1 |
| Watson, P | 1 |
| Wood, K | 1 |
| Guo, D | 1 |
| Hao, Z | 1 |
| Zhao, Y | 1 |
| Wang, B | 1 |
| Xu, H | 1 |
| Li, W | 1 |
| Min, D | 1 |
| Mao, X | 1 |
| Wu, K | 1 |
| Cao, Y | 1 |
| Guo, F | 1 |
| Zhu, S | 1 |
| Xie, N | 1 |
| Chen, T | 1 |
| Shaw, C | 1 |
| Xia, Z | 2 |
| Zhang, R | 1 |
| Wu, P | 1 |
| Hu, Y | 1 |
| Rai, S | 2 |
| Swarnkar, S | 1 |
| Liu, Y | 1 |
| Aisa, HA | 1 |
| Ji, C | 1 |
| Yang, N | 1 |
| Zhu, H | 1 |
| Zuo, P | 1 |
| Hwang, SH | 1 |
| Shin, EJ | 1 |
| Shin, TJ | 1 |
| Lee, BH | 1 |
| Choi, SH | 1 |
| Kang, J | 1 |
| Kim, HJ | 1 |
| Kwon, SH | 1 |
| Jang, CG | 1 |
| Lee, JH | 1 |
| Kim, HC | 1 |
| Nah, SY | 1 |
| Ali, S | 1 |
| Najmi, AK | 1 |
| Rahigude, A | 1 |
| Kaulaskar, S | 1 |
| Aswar, M | 1 |
| Otari, K | 1 |
| Ioannidis, P | 1 |
| Maiovis, P | 1 |
| Balamoutsos, G | 1 |
| Karacostas, D | 1 |
| Jung, IH | 1 |
| Jang, SE | 1 |
| Joh, EH | 1 |
| Chung, J | 1 |
| Han, MJ | 1 |
| Kim, DH | 1 |
| Nagakura, A | 1 |
| Shitaka, Y | 1 |
| Yarimizu, J | 1 |
| Matsuoka, N | 2 |
| Dhanjal, NS | 1 |
| Warren, JE | 1 |
| Patel, MC | 1 |
| Wise, RJ | 1 |
| Tokita, K | 1 |
| Yamazaki, S | 1 |
| Yamazaki, M | 1 |
| Mutoh, S | 1 |
| Morey, CE | 1 |
| Cilo, M | 1 |
| Berry, J | 1 |
| Cusick, C | 1 |
| Jovanovski, D | 1 |
| Zakzanis, KK | 1 |
| Brassen, S | 1 |
| Adler, G | 1 |
| Leroi, I | 1 |
| Brandt, J | 1 |
| Reich, SG | 1 |
| Lyketsos, CG | 1 |
| Grill, S | 1 |
| Thompson, R | 1 |
| Marsh, L | 1 |
| Buccafusco, JJ | 1 |
| Terry, AV | 1 |
| Amato, MP | 1 |
| Dong, H | 1 |
| Csernansky, CA | 1 |
| Martin, MV | 1 |
| Bertchume, A | 1 |
| Vallera, D | 1 |
| Csernansky, JG | 1 |
| Sonkusare, S | 1 |
| Srinivasan, K | 1 |
| Kaul, C | 1 |
| Ramarao, P | 1 |
| Yamada, K | 1 |
| Takayanagi, M | 1 |
| Kamei, H | 1 |
| Nagai, T | 1 |
| Dohniwa, M | 1 |
| Kobayashi, K | 1 |
| Yoshida, S | 1 |
| Ohhara, T | 1 |
| Takuma, K | 1 |
| Nabeshima, T | 1 |
| Tsao, JW | 1 |
| Heilman, KM | 1 |
| Takahata, K | 1 |
| Minami, A | 1 |
| Kusumoto, H | 1 |
| Shimazu, S | 1 |
| Yoneda, F | 1 |
| Jia, F | 1 |
| Kato, M | 1 |
| Dai, H | 1 |
| Xu, A | 1 |
| Okuda, T | 1 |
| Sakurai, E | 1 |
| Okamura, N | 1 |
| Lovenberg, TW | 1 |
| Barbier, A | 1 |
| Carruthers, NI | 1 |
| Iinuma, K | 1 |
| Yanai, K | 1 |
| Crowell, TA | 1 |
| Paramadevan, J | 1 |
| Abdullah, L | 1 |
| Mullan, M | 1 |
| Hildebrandt, H | 1 |
| Bussmann-Mork, B | 1 |
| Schwendemann, G | 1 |
| Birks, J | 1 |
| Flicker, L | 1 |
| Dimitrova, DS | 1 |
| Getova-Spassova, DP | 1 |
| Fujiki, M | 2 |
| Hikawa, T | 2 |
| Abe, T | 2 |
| Ishii, K | 2 |
| Kobayashi, H | 2 |
| Prakash, J | 1 |
| Kotwal, A | 1 |
| Prabhu, H | 1 |
| Petersen, R | 1 |
| Rozzini, L | 1 |
| Costardi, D | 1 |
| Chilovi, BV | 1 |
| Franzoni, S | 1 |
| Trabucchi, M | 1 |
| Padovani, A | 1 |
| Yamamoto, Y | 3 |
| Adachi, Y | 1 |
| Fujii, Y | 2 |
| Kamei, C | 3 |
| Yoo, JH | 1 |
| Valdovinos, MG | 1 |
| Williams, DC | 1 |
| Hamberger, MJ | 1 |
| Palmese, CA | 1 |
| Scarmeas, N | 2 |
| Weintraub, D | 1 |
| Choi, H | 1 |
| Hirsch, LJ | 1 |
| Anderson, KE | 1 |
| Brickman, AM | 1 |
| Flynn, J | 1 |
| Van Heertum, R | 1 |
| Sackeim, H | 1 |
| Marder, KS | 1 |
| Bell, K | 1 |
| Moeller, JR | 1 |
| Stern, Y | 1 |
| Salloway, S | 1 |
| Correia, S | 1 |
| Richardson, S | 1 |
| Mikami, A | 2 |
| Masuoka, T | 1 |
| Yasuda, M | 1 |
| Kelly, T | 1 |
| Cachard-Chastel, M | 1 |
| Devers, S | 1 |
| Sicsic, S | 1 |
| Langlois, M | 1 |
| Lezoualc'h, F | 1 |
| Gardier, AM | 1 |
| Belzung, C | 1 |
| Watanabe, T | 1 |
| Iwasaki, K | 1 |
| Ishikane, S | 1 |
| Naitou, T | 1 |
| Yoshimitsu, Y | 1 |
| Yamagata, N | 1 |
| Ozdemir, MB | 1 |
| Takasaki, K | 1 |
| Egashira, N | 1 |
| Mishima, K | 1 |
| Fujiwara, M | 1 |
| Devi, G | 2 |
| Massimi, S | 1 |
| Schultz, S | 1 |
| Khosrowshahi, L | 1 |
| Laakso, UK | 1 |
| Rueda, N | 1 |
| Flórez, J | 1 |
| Martínez-Cué, C | 1 |
| Singh, SP | 1 |
| Song, IU | 1 |
| Kim, JS | 1 |
| Ryu, SY | 1 |
| Lee, SB | 1 |
| An, JY | 1 |
| Lee, KS | 1 |
| Sharma, B | 1 |
| Singh, M | 1 |
| Jaggi, AS | 1 |
| Kubo, T | 1 |
| Kamida, T | 1 |
| Sugita, K | 1 |
| Doaga, A | 1 |
| Lee, TJ | 1 |
| Russell, R | 1 |
| Nair, R | 1 |
| Taverni, JP | 1 |
| Seliger, G | 1 |
| Lichtman, SW | 1 |
| Post, SG | 1 |
| Jacobsen, FM | 1 |
| Comas-Díaz, L | 1 |
| Kwak, YT | 1 |
| Han, IW | 1 |
| Baik, J | 1 |
| Koo, MS | 1 |
| Silver, J | 1 |
| Masanic, CA | 1 |
| Bayley, MT | 1 |
| VanReekum, R | 1 |
| Simard, M | 1 |
| Chen, Z | 1 |
| Xu, AJ | 1 |
| Li, R | 1 |
| Wei, EQ | 1 |
| Higgins, GA | 1 |
| Enderlin, M | 1 |
| Fimbel, R | 1 |
| Haman, M | 1 |
| Grottick, AJ | 1 |
| Soriano, M | 1 |
| Richards, JG | 1 |
| Kemp, JA | 1 |
| Gill, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| EMRESERVA A Program to Enhace Cognitive Reserve in Patients With Multiple Scleorisis[NCT05546424] | 58 participants (Anticipated) | Observational | 2022-05-19 | Recruiting | |||
| Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis[NCT02988401] | Phase 1/Phase 2 | 105 participants (Actual) | Interventional | 2017-12-01 | Completed | ||
| The Efficacy of 23mg Versus 10mg of Donepezil in ParkInson's Disease With Dementia[NCT02415062] | Phase 2 | 150 participants (Anticipated) | Interventional | 2015-07-31 | Recruiting | ||
| Does Memantine Improve Verbal Memory Task Performance in Subjects With Localization-related Epilepsy and Memory Dysfunction? A Randomized, Double-Blind, Placebo-Controlled Trial[NCT01054599] | 29 participants (Actual) | Interventional | 2009-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The BDI-II is a 21-question multiple-choice self-report inventory test for measuring the severity of depression. Scores range from zero to 63; higher scores indicate greater depression. In order to account for all contributed data (even for those who did not complete the study but contributed some post-randomization data in the active study phase), the analyses include the BDI-II scores acquired within the active treatment phase (from baseline to week 24 visit). We then calculated and report the average change per week in the scores. (NCT02988401)
Timeframe: Up to week 24 visit
| Intervention | score on a scale (Mean) |
|---|---|
| Intranasal Insulin 20 International Units | -0.022 |
| Intranasal Insulin 10 International Units | -0.019 |
| Placebo | -0.045 |
This is a visual, nonverbal test of learning and memory. Scores range from zero to 12; higher is better. In order to account for all contributed data (even for those who did not complete the study but contributed some post-randomization data in the active study phase), the analyses include the BVMT-R delayed recall scores acquired within the active treatment phase (from baseline to week 24 visit). We then calculated and report the average change per week in the score. (NCT02988401)
Timeframe: Up to week 24 visit
| Intervention | score on a scale (Mean) |
|---|---|
| Intranasal Insulin 20 International Units | 0.027 |
| Intranasal Insulin 10 International Units | 0.059 |
| Placebo | 0.030 |
This is a verbal learning and memory test. Scores range from zero to 16; a higher number is better. In order to account for all contributed data (even for those who did not complete the study but contributed some post-randomization data in the active study phase), the primary analyses include the CVLT-II scores acquired within the active treatment phase (from baseline to week 24 visit). We then calculated and report the average change per week in the score. (NCT02988401)
Timeframe: Up to week 24 visit
| Intervention | score on a scale (Mean) |
|---|---|
| Intranasal Insulin 20 International Units | 0.082 |
| Intranasal Insulin 10 International Units | 0.021 |
| Placebo | 0.020 |
This test measures phonemic fluency. The test scores the number of words a participant can provide that begin with a specified letter within one minute, such that scores range from zero (worst) to an infinite number (better). Total score is sum of three 60-second trials. In order to account for all contributed data (even for those who did not complete the study but contributed some post-randomization data in the active study phase), the primary analyses include the COWAT scores acquired within the active treatment phase (from baseline to week 24 visit). We then calculated and report the average change per week in the score. (NCT02988401)
Timeframe: Up to week 24 visit
| Intervention | score on a scale (Mean) |
|---|---|
| Intranasal Insulin 20 International Units | 0.090 |
| Intranasal Insulin 10 International Units | 0.070 |
| Placebo | 0.021 |
This test measures executive functioning, concept formation, and cognitive flexibility. Scores range from zero to 16; higher is better. In order to account for all contributed data (even for those who did not complete the study but contributed some post-randomization data in the active study phase), the analyses include DKEFS correct sort scores acquired within the active treatment phase (from baseline to week 24 visit). We then calculated and report the average change per week in the score. (NCT02988401)
Timeframe: Up to week 24 visit
| Intervention | score on a scale (Mean) |
|---|---|
| Intranasal Insulin 20 International Units | -0.001 |
| Intranasal Insulin 10 International Units | 0.027 |
| Placebo | 0.002 |
Judgment of Line Orientation Test measures a person's ability to match the angle and orientation of lines in space. Scores range from zero to 30; higher is better. In order to account for all contributed data (even for those who did not complete the study but contributed some post-randomization data in the active study phase), the analyses include JLO data acquired within the active treatment phase (from baseline to week 24 visit). We then calculated and report the average change per week in the score. (NCT02988401)
Timeframe: Up to week 24 visit
| Intervention | score on a scale (Mean) |
|---|---|
| Intranasal Insulin 20 International Units | -0.031 |
| Intranasal Insulin 10 International Units | 0.047 |
| Placebo | -0.005 |
"The Rao-version of the PASAT evaluates processing speed, working memory, and basic addition skills. Scores range from zero to 60; higher is better. Herein we present 3-second PASAT results (PASAT-3). In order to account for all contributed data (even for those who did not complete the study but contributed some post-randomization data in the active study phase), the analyses include PASAT-3 scores acquired within the active treatment phase (from baseline to week 24 visit). We then calculated and report the average change per week in the SDMT." (NCT02988401)
Timeframe: Up to week 24 visit
| Intervention | score on a scale (Mean) |
|---|---|
| Intranasal Insulin 20 International Units | 0.372 |
| Intranasal Insulin 10 International Units | 0.363 |
| Placebo | 0.212 |
This task will be performed at five study visits. The SDMT is one of the most commonly used tests to assess processing speed in the MS population and is included in the Minimal Assessment of Cognitive Function in MS (MACFIMS). Higher scores reflect a better outcome (range 0 to 110). In order to account for all contributed data (even for those who did not complete the study but contributed some post-randomization data in the active study phase), the primary analyses include the SDMTs acquired within the active treatment phase (from baseline to week 24 visit). We then calculated and report the average change per week in the SDMT. (NCT02988401)
Timeframe: Up to week 24 visit
| Intervention | score on a scale (Mean) |
|---|---|
| Intranasal Insulin 20 International Units | 0.145 |
| Intranasal Insulin 10 International Units | 0.207 |
| Placebo | 0.163 |
The sleep questionnaire asks subjects to report various aspects related to their sleep routine. Scores range from zero to 21; higher score indicates worse sleep quality. In order to account for all contributed data (even for those who did not complete the study but contributed some post-randomization data in the active study phase), the analyses include the PSQIs acquired within the active treatment phase (from baseline to week 24 visit). We then calculated and report the average change per week in the score. (NCT02988401)
Timeframe: Up to week 24 visit
| Intervention | score on a scale (Mean) |
|---|---|
| Intranasal Insulin 20 International Units | -0.026 |
| Intranasal Insulin 10 International Units | 0.035 |
| Placebo | -0.045 |
FAMS is a self-reported health-related quality-of-life instrument for people with multiple sclerosis. Subjects rate six quality-of-life domains: Mobility, Symptoms, Emotional well-being, General contentment, Thinking/fatigue, and Family/social well-being. Scores range from zero to 176; higher scores indicate better health-related quality of life. In order to account for all contributed data (even for those who did not complete the study but contributed some post-randomization data in the active study phase), the analyses include the FAMS scores acquired within the active treatment phase (from baseline to week 24 visit). We then calculated and report the average change per week in the score. (NCT02988401)
Timeframe: Up to week 24 visit
| Intervention | score on a scale (Mean) |
|---|---|
| Intranasal Insulin 20 International Units | 0.056 |
| Intranasal Insulin 10 International Units | 0.051 |
| Placebo | 0.240 |
An adverse event will be defined as any occurrence or worsening of an undesirable or unintended sign, symptom (or abnormal laboratory test), or disease temporally associated with the use of a medicinal product or intervention, whether or not it is considered related to the product/intervention. We report overall adverse events in the relevant section. Here, we report adverse events that led to study discontinuation. (NCT02988401)
Timeframe: Up to week 24 visit
| Intervention | Participants (Count of Participants) |
|---|---|
| Intranasal Insulin 20 International Units | 3 |
| Intranasal Insulin 10 International Units | 2 |
| Placebo | 1 |
Fingerstick blood glucose levels were monitored twice within the 90 minutes following the first dose administration of study drug for the first 15 participants. (NCT02988401)
Timeframe: At the baseline visit, monitored twice within the 90 minutes following the first dose administration of study drug
| Intervention | mg/dL (Mean) | |
|---|---|---|
| First timepoint | Second timepoint | |
| Intranasal Insulin 10 International Units | 95.8 | 92.2 |
| Intranasal Insulin 20 International Units | 97.8 | 88.4 |
| Placebo | 90.0 | 87.8 |
SRT-CLTR (range 0-72; higher scores indicate better memory), and 7-24 Spatial Memory Test (range 0-35; scores are summed across the 5 learning trials, with higher scores indicating better memory) scores will be assessed across the first (baseline) and third (post-open label memantine) testing sessions. These measures are considered to be scores on a scale, rather than standard units. The hypothesis was that subjects randomized to memantine would demonstrate sustained improvement from baseline, while the placebo group would demonstrate improvements after taking open label memantine (compared to baseline). (NCT01054599)
Timeframe: 26 weeks
| Intervention | scores on a scale (Mean) | |||
|---|---|---|---|---|
| SRT CLTR Baseline | SRT CLTR Post-Open Label | 7-24 Total Learning Baseline | 7-24 Total Learning Post-Open Label | |
| Memantine | 32.67 | 40.33 | 30.33 | 31.67 |
| Sugar Pill | 22.71 | 40.29 | 28.14 | 32.43 |
Change scores from pre- to post-treatment/placebo were calculated for the primary outcome measures, the Selective Reminding Test Continuous Long-Term Retrieval (range 0-72; higher scores indicate better memory) and 7-24 Spatial Recall Test Total Learning (range 0-35; total correct across 5 learning trials are summed, with higher scores indicating better memory) scores. These measures are scores on a scale, rather than representing standard units. (NCT01054599)
Timeframe: 13 weeks
| Intervention | scores on a scale (Mean) | |
|---|---|---|
| 7-24 Spatial Recall Tests Learning Change Score | SRT Continuous Long-Term Retrieval Change Score | |
| Memantine | 1.00 | 4.38 |
| Sugar Pill | 1.78 | 8.11 |
9 reviews available for donepezil and Age-Related Memory Disorders
| Article | Year |
|---|---|
Pharmacological treatment for memory disorder in multiple sclerosis.
Topics: Adult; Donepezil; Ginkgo biloba; Humans; Indans; Memantine; Memory Disorders; Multiple Sclerosis; Ne | 2017 |
Pharmacological treatment for memory disorder in multiple sclerosis.
Topics: Adult; Donepezil; Ginkgo biloba; Humans; Indans; Memantine; Memory Disorders; Middle Aged; Multiple | 2013 |
[Memory-enhancing drugs].
Topics: Animals; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Cyclic AMP Response Element-Binding Pro | 2014 |
Pharmacologic treatment for memory disorder in multiple sclerosis.
Topics: Adult; Donepezil; Ginkgo biloba; Humans; Indans; Memantine; Memory Disorders; Middle Aged; Multiple | 2011 |
Donepezil for mild cognitive impairment.
Topics: Donepezil; Humans; Indans; Memory Disorders; Nootropic Agents; Piperidines; Randomized Controlled Tr | 2006 |
Relevance of donepezil in enhancing learning and memory in special populations: a review of the literature.
Topics: Alzheimer Disease; Animals; Attention; Attention Deficit Disorder with Hyperactivity; Autistic Disor | 2007 |
Clinical inquiries. What could be behind your elderly patient's subjective memory complaints?
Topics: Aged; Cognition; Depression; Donepezil; Geriatric Assessment; Ginkgo biloba; Humans; Indans; Memory | 2008 |
The fear of forgetfulness: a grassroots approach to an ethics of Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Ethics, Medical; Female; Humans; Inda | 1998 |
Approaches to memory loss in neuropsychiatric disorders.
Topics: Aging; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Cholinesterase Inhibitors; Dementia; D | 2000 |
19 trials available for donepezil and Age-Related Memory Disorders
| Article | Year |
|---|---|
The effect of donepezil hydrochloride on post-COVID memory impairment: A randomized controlled trial.
Topics: COVID-19; Donepezil; Executive Function; Humans; Iran; Memory Disorders; Quality of Life | 2023 |
Efficacy of donepezil for the attenuation of memory deficits associated with electroconvulsive therapy.
Topics: Adult; Cholinesterase Inhibitors; Donepezil; Double-Blind Method; Electroconvulsive Therapy; Female; | 2020 |
Effect of cholinergic neurotransmission modulation on visual spatial paired associate learning in healthy human adults.
Topics: Adolescent; Adult; Cholinesterase Inhibitors; Cognition Disorders; Cross-Over Studies; Donepezil; Do | 2013 |
Specific impairments in visuospatial working and short-term memory following low-dose scopolamine challenge in healthy older adults.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Cholinesterase Inhibitors; Donepezil; Dose-Response R | 2008 |
Acetylcholinesterase inhibitor in combination with cognitive training in older adults.
Topics: Aged; Aged, 80 and over; Cholinesterase Inhibitors; Combined Modality Therapy; Donepezil; Double-Bli | 2008 |
Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis.
Topics: Adolescent; Adult; Cholinesterase Inhibitors; Donepezil; Double-Blind Method; Female; Humans; Indans | 2011 |
Auditory cortical function during verbal episodic memory encoding in Alzheimer's disease.
Topics: Adult; Aged; Aged, 80 and over; Alzheimer Disease; Attention; Auditory Cortex; Auditory Perceptual D | 2013 |
Short-term effects of acetylcholinesterase inhibitor treatment on EEG and memory performance in Alzheimer patients: an open, controlled trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Donepezil; Electr | 2003 |
Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Cholinesterase Inhibitors; Dementia; Donepezil; Double-Blind Method; Female | 2004 |
Beneficial effect of cholinesterase inhibitor medications on recognition memory performance in mild to moderate Alzheimer's disease: preliminary findings.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Female; Humans; In | 2006 |
Group therapy for memory impaired patients: a partial remediation is possible.
Topics: Aged; Analysis of Variance; Attention; Donepezil; Female; Humans; Indans; Intelligence Tests; Male; | 2006 |
Reduced short latency afferent inhibition in diffuse axonal injury patients with memory impairment.
Topics: Adult; Afferent Pathways; Differential Threshold; Diffuse Axonal Injury; Donepezil; Female; Humans; | 2006 |
Therapeutic and prophylactic utility of the memory-enhancing drug donepezil hydrochloride on cognition of patients undergoing electroconvulsive therapy: a randomized controlled trial.
Topics: Adult; Cognition; Donepezil; Electroconvulsive Therapy; Humans; Indans; Male; Memory; Memory Disorde | 2006 |
Efficacy of cognitive rehabilitation in patients with mild cognitive impairment treated with cholinesterase inhibitors.
Topics: Activities of Daily Living; Aged; Cholinesterase Inhibitors; Cognition Disorders; Combined Modality | 2007 |
A randomized, double-blind, placebo-controlled trial of donepezil to improve memory in epilepsy.
Topics: Cholinesterase Inhibitors; Cognition Disorders; Cross-Over Studies; Donepezil; Dose-Response Relatio | 2007 |
Key lessons learned from short-term treatment trials of cholinesterase inhibitors for amnestic MCI.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Cohort Studies; Donepezil; | 2008 |
A double-blind, placebo-controlled trial of donepezil for the treatment of menopause-related cognitive loss.
Topics: Cholinesterase Inhibitors; Cognition Disorders; Donepezil; Double-Blind Method; Female; Humans; Inda | 2007 |
Donepezil for psychotropic-induced memory loss.
Topics: Adult; Ambulatory Care; Cholinesterase Inhibitors; Constipation; Depressive Disorder; Diarrhea; Dizz | 1999 |
Open-label study of donepezil in traumatic brain injury.
Topics: Adult; Brain Injuries; Chronic Disease; Donepezil; Humans; Indans; Male; Memory Disorders; Mental Di | 2001 |
109 other studies available for donepezil and Age-Related Memory Disorders
| Article | Year |
|---|---|
Design, synthesis and evaluation of scutellarein-O-alkylamines as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amines; Amyloid beta-Peptides; Animals; Antioxidants; Apige | 2015 |
Design, synthesis and evaluation of novel ferulic acid-O-alkylamine derivatives as potential multifunctional agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Blood-Brain Barrier; Butyrylcholine | 2017 |
Design, Synthesis, and Evaluation of Orally Bioavailable Quinoline-Indole Derivatives as Innovative Multitarget-Directed Ligands: Promotion of Cell Proliferation in the Adult Murine Hippocampus for the Treatment of Alzheimer's Disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Cell Proliferation; Drug Des | 2018 |
In silico studies, synthesis and pharmacological evaluation to explore multi-targeted approach for imidazole analogues as potential cholinesterase inhibitors with neuroprotective role for Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Butyrylcholinesterase; Cholinesterase Inhibitors; | 2018 |
Development of chalcone-O-alkylamine derivatives as multifunctional agents against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Biological Tr | 2019 |
New Dual Small Molecules for Alzheimer's Disease Therapy Combining Histamine H
Topics: Alzheimer Disease; Animals; Calcium Channel Blockers; Cholinesterase Inhibitors; Humans; Memory Diso | 2019 |
Scopolamine and MK-801 impair recognition memory in a new spontaneous object exploration task in monkeys.
Topics: Acetylcholinesterase; Animals; Callithrix; Dizocilpine Maleate; Donepezil; Excitatory Amino Acid Ant | 2021 |
[Galangin alleviates learning and memory impairments in APP/PS1 double- transgenic mice by regulating Akt/MEF2D/Beclin-1 signaling pathway].
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amyl | 2022 |
Protective effects of isofraxidin against scopolamine-induced cognitive and memory impairments in mice involve modulation of the BDNF-CREB-ERK signaling pathway.
Topics: Acetylcholinesterase; Animals; Brain-Derived Neurotrophic Factor; Cognition; Coumarins; Cyclic AMP R | 2022 |
Thymus daenensis extract prevents scopolamine‑induced memory impairment through declining oxidative stress in rats.
Topics: Animals; Antioxidants; Donepezil; Glutathione; Male; Malondialdehyde; Maze Learning; Memory Disorder | 2022 |
Thiazolidin-4-one prevents against memory deficits, increase in phosphorylated tau protein, oxidative damage and cholinergic dysfunction in Alzheimer disease model: Comparison with donepezil drug.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antioxidants; Cholinesterase Inhibitors; Disease M | 2023 |
Thiazolidin-4-one prevents against memory deficits, increase in phosphorylated tau protein, oxidative damage and cholinergic dysfunction in Alzheimer disease model: Comparison with donepezil drug.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antioxidants; Cholinesterase Inhibitors; Disease M | 2023 |
Thiazolidin-4-one prevents against memory deficits, increase in phosphorylated tau protein, oxidative damage and cholinergic dysfunction in Alzheimer disease model: Comparison with donepezil drug.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antioxidants; Cholinesterase Inhibitors; Disease M | 2023 |
Thiazolidin-4-one prevents against memory deficits, increase in phosphorylated tau protein, oxidative damage and cholinergic dysfunction in Alzheimer disease model: Comparison with donepezil drug.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antioxidants; Cholinesterase Inhibitors; Disease M | 2023 |
Aniba canelilla (Kunth) Mez essential oil and its primary constituent, 1-nitro-2-phenylethane, inhibits acetylcholinesterase and reverse memory impairment in rodents.
Topics: Acetylcholinesterase; Animals; Donepezil; Lauraceae; Maze Learning; Memory Disorders; Mice; Oils, Vo | 2023 |
Aniba canelilla (Kunth) Mez essential oil and its primary constituent, 1-nitro-2-phenylethane, inhibits acetylcholinesterase and reverse memory impairment in rodents.
Topics: Acetylcholinesterase; Animals; Donepezil; Lauraceae; Maze Learning; Memory Disorders; Mice; Oils, Vo | 2023 |
Aniba canelilla (Kunth) Mez essential oil and its primary constituent, 1-nitro-2-phenylethane, inhibits acetylcholinesterase and reverse memory impairment in rodents.
Topics: Acetylcholinesterase; Animals; Donepezil; Lauraceae; Maze Learning; Memory Disorders; Mice; Oils, Vo | 2023 |
Aniba canelilla (Kunth) Mez essential oil and its primary constituent, 1-nitro-2-phenylethane, inhibits acetylcholinesterase and reverse memory impairment in rodents.
Topics: Acetylcholinesterase; Animals; Donepezil; Lauraceae; Maze Learning; Memory Disorders; Mice; Oils, Vo | 2023 |
Therapeutic potential of blackberry extract in the preventing memory deficits and neurochemical alterations in the cerebral cortex, hippocampus and cerebellum of a rat model with amnesia.
Topics: Acetylcholinesterase; Amnesia; Animals; Antioxidants; Cerebellum; Cerebral Cortex; Donepezil; Hippoc | 2023 |
Edaravone Improves Streptozotocin-Induced Memory Impairment via Alleviation of Behavioral Dysfunction, Oxidative Stress, Inflammation, and Histopathological Parameters.
Topics: Alzheimer Disease; Animals; Antioxidants; Disease Models, Animal; Donepezil; Edaravone; Inflammation | 2023 |
Olax subscorpioidea prevented scopolamine-induced memory impairment through the prevention of oxido-inflammatory damage and modulation of cholinergic transmission.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Cholinergic Agents; Donepezil; Hippocampus; Maze L | 2024 |
Donepezil Attenuates Obesity-Associated Oxidative Stress and Central Inflammation and Improves Memory Deficit in Mice Fed a High-Fat Diet.
Topics: Animals; Diet, High-Fat; Donepezil; Glycation End Products, Advanced; Inflammation; Insulin Resistan | 2019 |
Cognitive Facilitation and Antioxidant Effects of an Essential Oil Mix on Scopolamine-Induced Amnesia in Rats: Molecular Modeling of In Vitro and In Vivo Approaches.
Topics: Acetylcholinesterase; Amnesia; Animals; Antioxidants; Behavior Rating Scale; Brain; Butyrylcholinest | 2020 |
Evaluation of the neuroprotective effect of donepezil in type 2 diabetic rats.
Topics: Alzheimer Disease; Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Donepezil; H | 2021 |
Shaddock (
Topics: Acetylcholinesterase; Animals; Antioxidants; Butyrylcholinesterase; Cholinergic Agents; Citrus; Cogn | 2022 |
Delay-dependent cholinergic modulation of visual short-term memory in rhesus macaques.
Topics: Animals; Behavior, Animal; Cholinesterase Inhibitors; Dementia; Disease Models, Animal; Donepezil; M | 2021 |
Gelidiella acerosa protects against Aβ 25-35-induced toxicity and memory impairment in Swiss Albino mice: an in vivo report.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases | 2017 |
Spatial recognition test: A novel cognition task for assessing topographical memory in mice.
Topics: Alzheimer Disease; Animals; Cognition; Disease Models, Animal; Donepezil; Indans; Levetiracetam; Mal | 2017 |
Effects of acute administration of donepezil or memantine on sleep-deprivation-induced spatial memory deficit in young and aged non-human primate grey mouse lemurs (Microcebus murinus).
Topics: Aging; Alzheimer Disease; Animals; Cheirogaleidae; Disease Models, Animal; Donepezil; Indans; Male; | 2017 |
Synergistic enhancing-memory effect of donepezil and S 47445, an AMPA positive allosteric modulator, in middle-aged and aged mice.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Alzheimer Disease; Animals; Benzoxazines; | 2018 |
Stabilized Low-n Amyloid-β Oligomers Induce Robust Novel Object Recognition Deficits Associated with Inflammatory, Synaptic, and GABAergic Dysfunction in the Rat.
Topics: Amyloid beta-Peptides; Animals; Brain; Cognition; Disease Models, Animal; Donepezil; Female; gamma-A | 2018 |
Protective effect of betulinic acid against intracerebroventricular streptozotocin induced cognitive impairment and neuronal damage in rats: Possible neurotransmitters and neuroinflammatory mechanism.
Topics: Acetylcholinesterase; Animals; Betulinic Acid; Cognitive Dysfunction; Disease Models, Animal; Donepe | 2018 |
Central cholinergic system mediates working memory deficit induced by anesthesia/surgery in adult mice.
Topics: Acetylcholinesterase; Anesthetics, Inhalation; Animals; Choline O-Acetyltransferase; Cholinergic Age | 2018 |
SUVN-502, a novel, potent, pure, and orally active 5-HT6 receptor antagonist: pharmacological, behavioral, and neurochemical characterization.
Topics: Acetylcholine; Animals; Behavior, Animal; Brain; Brain Waves; CHO Cells; Cricetulus; Culture Media, | 2019 |
New procognitive enhancers acting at the histamine H3 and AMPA receptors reverse natural forgetting in mice: comparisons with donepezil and memantine in the object recognition task.
Topics: Animals; Azabicyclo Compounds; Benzamides; Benzoxazines; Cognition; Donepezil; Histamine Agonists; M | 2019 |
Jobelyn Attenuates Oxidative Stress and Improves Memory Performance in Mice Exposed to Anoxic Stress.
Topics: Animals; Biomarkers; Brain; Dietary Supplements; Disease Models, Animal; Donepezil; Glutathione; Hum | 2019 |
Studies of the Anti-amnesic Effects and Mechanisms of Single and Combined Use of Donepezil and Ginkgo Ketoester Tablet on Scopolamine-Induced Memory Impairment in Mice.
Topics: Acetylcholine; Acetylcholinesterase; Amnesia; Animals; Benzothiazoles; Biphenyl Compounds; Brain-Der | 2019 |
Spatial memory deficits in mice induced by chemotherapeutic agents are prevented by acetylcholinesterase inhibitors.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Behavior, Animal; Cholinest | 2019 |
Effects of the adenosine A2A antagonist istradefylline on cognitive performance in rats with a 6-OHDA lesion in prefrontal cortex.
Topics: Adenosine A2 Receptor Antagonists; Animals; Cognition; Cognition Disorders; Disease Models, Animal; | 2013 |
Attenuating Aβ1-42-induced toxicity by a novel acetylcholinesterase inhibitor.
Topics: Acetylcholinesterase; Amyloid beta-Peptides; Animals; Anthracenes; Cholinesterase Inhibitors; Donepe | 2013 |
Donepezil inhibits the amyloid-beta oligomer-induced microglial activation in vitro and in vivo.
Topics: Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents; Cells, Cultured; Donepezil; Hippocampus; I | 2014 |
Free radical scavenging effect of donepezil as the possible contribution to its memory enhancing activity in mice.
Topics: Animals; Antioxidants; Biomarkers; Donepezil; Free Radical Scavengers; Free Radicals; Glutathione; I | 2014 |
Novel multipotent AChEI-CCB attenuates hyperhomocysteinemia-induced memory deficits and Neuropathologies in rats.
Topics: Animals; Brain Diseases; Calcium Channel Blockers; Cholinesterase Inhibitors; Disease Models, Animal | 2014 |
Cognitive enhancing effect of the fermented Gumiganghwal-tang on scopolamine-induced memory impairment in mice.
Topics: Acetylcholinesterase; Animals; Avoidance Learning; Behavior, Animal; Cholinergic Antagonists; Cholin | 2016 |
Brain toxicity and inflammation induced in vivo in mice by the amyloid-β forty-two inducer aftin-4, a roscovitine derivative.
Topics: Adenine; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Anti-Inflammatory Age | 2015 |
Ameliorative effect of rosmarinic acid on scopolamine-induced memory impairment in rats.
Topics: Animals; Avoidance Learning; Cholinergic Antagonists; Cinnamates; Depsides; Donepezil; Indans; Male; | 2015 |
Protective effect of n-butanol extract from Alpinia oxyphylla on learning and memory impairments.
Topics: 1-Butanol; Alpinia; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Avoidance | 2015 |
Procognitive effect of AC-3933 in aged mice, and synergistic effect of combination with donepezil in scopolamine-treated mice.
Topics: Aging; Animals; Donepezil; Drug Synergism; Flumazenil; GABA-A Receptor Agonists; Indans; Male; Maze | 2014 |
Donepezil improves learning and memory deficits in APP/PS1 mice by inhibition of microglial activation.
Topics: Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Antigens, CD; Antigens, Differentiat | 2015 |
Donepezil rescues spatial learning and memory deficits following traumatic brain injury independent of its effects on neurogenesis.
Topics: Animals; Brain Injuries; Dentate Gyrus; Disease Models, Animal; Donepezil; Female; Ganciclovir; Inda | 2015 |
The selective positive allosteric M1 muscarinic receptor modulator PQCA attenuates learning and memory deficits in the Tg2576 Alzheimer's disease mouse model.
Topics: Aging; Alzheimer Disease; Animals; Cholinergic Agents; Cholinesterase Inhibitors; Disease Models, An | 2015 |
[Design, synthesis and biological evaluation of novel [1,3] dioxolo [4,5-f]isoindolone derivatives].
Topics: Animals; Cholinesterase Inhibitors; Dioxoles; Donepezil; Drug Design; Indans; Inhibitory Concentrati | 2015 |
Protective effect of berberine, an isoquinoline alkaloid ameliorates ethanol-induced oxidative stress and memory dysfunction in rats.
Topics: Animals; Ascorbic Acid; Behavior, Animal; Berberine; Cerebral Cortex; Cholinesterase Inhibitors; Don | 2015 |
Protection by sigma-1 receptor agonists is synergic with donepezil, but not with memantine, in a mouse model of amyloid-induced memory impairments.
Topics: Amyloid beta-Peptides; Animals; Cholinesterase Inhibitors; Disease Models, Animal; Donepezil; Drug S | 2016 |
The dual-acting H3 receptor antagonist and AChE inhibitor UW-MD-71 dose-dependently enhances memory retrieval and reverses dizocilpine-induced memory impairment in rats.
Topics: Animals; Avoidance Learning; Benzothiazoles; Cholinesterase Inhibitors; Disease Models, Animal; Dizo | 2016 |
Ferulic acid ameliorates memory impairment in d-galactose-induced aging mouse model.
Topics: Acetylcholinesterase; Aging; Animals; Antioxidants; Brain; Caspase 3; Coumaric Acids; Disease Models | 2016 |
Rosmarinic acid protects against chronic ethanol-induced learning and memory deficits in rats.
Topics: Alcohol-Induced Disorders, Nervous System; Animals; Antioxidants; Avoidance Learning; Behavior, Anim | 2017 |
Cholinesterase inhibitors, donepezil and rivastigmine, attenuate spatial memory and cognitive flexibility impairment induced by acute ethanol in the Barnes maze task in rats.
Topics: Animals; Behavior, Animal; Cholinesterase Inhibitors; Cognition; Cognition Disorders; Disease Models | 2016 |
Fuzhisan ameliorates Aβ production and tau phosphorylation in hippocampal of 11month old APP/PS1 transgenic mice: A Western blot study.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Blotting, Western; Disease Models, Animal; Donepe | 2016 |
Anti-amnestic Effect of Curcumin in Combination with Donepezil, an Anticholinesterase Drug: Involvement of Cholinergic System.
Topics: Adenosine Deaminase; Animals; Brain; Catalase; Cholinergic Neurons; Cholinesterase Inhibitors; Curcu | 2017 |
Inhibitor of Phosphodiestearse-4 improves memory deficits, oxidative stress, neuroinflammation and neuropathological alterations in mouse models of dementia of Alzheimer's Type.
Topics: Acetylcholinesterase; Aging; Alzheimer Disease; Animals; Antioxidants; Brain; Cholinesterase Inhibit | 2017 |
Multifunctional Compound AD-35 Improves Cognitive Impairment and Attenuates the Production of TNF-α and IL-1β in an Aβ25-35-induced Rat Model of Alzheimer's Disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Astrocytes; Brain; Cell Line, Tumor; Cholinestera | 2017 |
Effect of citalopram in treating hypersexuality in an Alzheimer's disease case.
Topics: Alzheimer Disease; Brain; Citalopram; Cognition Disorders; Disease Progression; Donepezil; Fluorodeo | 2008 |
Early postnatal maternal deprivation in rats induces memory deficits in adult life that can be reversed by donepezil and galantamine.
Topics: Acetylcholine; Acetylcholinesterase; Aging; Animals; Animals, Newborn; Brain; Disease Models, Animal | 2009 |
Successful use of donepezil in treatment of cognitive impairment caused by maintenance electroconvulsive therapy: a case report.
Topics: Adult; Cholinesterase Inhibitors; Cognition Disorders; Donepezil; Electroconvulsive Therapy; Female; | 2009 |
Scopolamine-induced deficits in social memory in mice: reversal by donepezil.
Topics: Animals; Anti-Anxiety Agents; Cholinesterase Inhibitors; Diazepam; Donepezil; Dose-Response Relation | 2009 |
Okadaic acid (ICV) induced memory impairment in rats: a suitable experimental model to test anti-dementia activity.
Topics: Animals; Brain; Calcium Signaling; Cholinesterase Inhibitors; Dementia; Disease Models, Animal; Done | 2010 |
Phencyclidine withdrawal disrupts episodic-like memory in rats: reversal by donepezil but not clozapine.
Topics: Animals; Clozapine; Donepezil; Indans; Male; Memory Disorders; Memory, Episodic; Phencyclidine; Pipe | 2010 |
Insulin receptor signaling in rat hippocampus: a study in STZ (ICV) induced memory deficit model.
Topics: Animals; Blood Glucose; Chromones; Disease Models, Animal; Donepezil; Gene Expression; Hippocampus; | 2011 |
Protection of cholinergic and antioxidant system contributes to the effect of berberine ameliorating memory dysfunction in rat model of streptozotocin-induced diabetes.
Topics: Acetylcholine; Administration, Oral; Analysis of Variance; Animals; Antioxidants; Ascorbic Acid; Ber | 2011 |
Cholinesterase inhibitors improve both memory and complex learning in aged beagle dogs.
Topics: Aging; Analysis of Variance; Animals; Behavior, Animal; Cholinergic Antagonists; Cholinesterase Inhi | 2011 |
ICV STZ induced impairment in memory and neuronal mitochondrial function: A protective role of nicotinic receptor.
Topics: Analysis of Variance; Animals; Blood Glucose; Brain; Calcium; Caspase 3; Cell Death; Cholinesterase | 2011 |
Two novel 5-HT6 receptor antagonists ameliorate scopolamine-induced memory deficits in the object recognition and object location tasks in Wistar rats.
Topics: Animals; Cholinesterase Inhibitors; Donepezil; Exploratory Behavior; Guanidines; Indans; Male; Maze | 2011 |
A modified formulation of Chinese traditional medicine improves memory impairment and reduces Aβ level in the Tg-APPswe/PS1dE9 mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Apoptosis; Behavi | 2011 |
SenseCam improves memory for recent events and quality of life in a patient with memory retrieval difficulties.
Topics: Cholinesterase Inhibitors; Cognitive Dysfunction; Cues; Donepezil; Environmental Monitoring; Female; | 2011 |
Isoflurane-induced spatial memory impairment in mice is prevented by the acetylcholinesterase inhibitor donepezil.
Topics: Acetylcholinesterase; Anesthetics, Inhalation; Animals; Blood Gas Analysis; Blotting, Western; Choli | 2011 |
Donepezil attenuates hippocampal neuronal damage and cognitive deficits after global cerebral ischemia in gerbils.
Topics: Animals; Brain Ischemia; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Cell Death; Cognition D | 2012 |
Memory defect induced by β-amyloid plus glutamate receptor agonist is alleviated by catalpol and donepezil through different mechanisms.
Topics: Amyloid beta-Peptides; Animals; Cells, Cultured; Donepezil; Excitatory Amino Acid Agonists; Female; | 2012 |
A study on neuroinflammatory marker in brain areas of okadaic acid (ICV) induced memory impaired rats.
Topics: Animals; Behavior, Animal; Biomarkers; Blotting, Western; Donepezil; Excitatory Amino Acid Antagonis | 2012 |
Effects of Gossypium herbaceam extract administration on the learning and memory function in the naturally aged rats: neuronal niche improvement.
Topics: Aging; Analysis of Variance; Animals; Avoidance Learning; Behavior, Animal; Brain-Derived Neurotroph | 2012 |
Gintonin, a ginseng-derived lysophosphatidic acid receptor ligand, attenuates Alzheimer's disease-related neuropathies: involvement of non-amyloidogenic processing.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Analysis of Variance; Anim | 2012 |
Okadaic acid induced neurotoxicity leads to central cholinergic dysfunction in rats.
Topics: Acetylcholine; Acetylcholinesterase; Animals; Biomarkers; Donepezil; Gene Expression Regulation; Hip | 2012 |
Participation of antioxidant and cholinergic system in protective effect of naringenin against type-2 diabetes-induced memory dysfunction in rats.
Topics: Animals; Antioxidants; Blood Glucose; Body Weight; Cholinesterase Inhibitors; Cholinesterases; Diabe | 2012 |
Acute Pisa syndrome after administration of a single dose of donepezil.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Dystonia; Female; Humans; Indans; Mem | 2012 |
Lancemaside A isolated from Codonopsis lanceolata and its metabolite echinocystic acid ameliorate scopolamine-induced memory and learning deficits in mice.
Topics: Acetylcholinesterase; Animals; Avoidance Learning; Brain-Derived Neurotrophic Factor; Cholinesterase | 2012 |
Characterization of cognitive deficits in a transgenic mouse model of Alzheimer's disease and effects of donepezil and memantine.
Topics: Alzheimer Disease; Animals; Brain; Cholinesterase Inhibitors; Cyclic AMP Response Element-Binding Pr | 2013 |
Combination of a novel antidementia drug FK960 with donepezil synergistically improves memory deficits in rats.
Topics: Aging; Animals; Avoidance Learning; Basal Nucleus of Meynert; Benzamides; Donepezil; Dose-Response R | 2002 |
The effect of Aricept in persons with persistent memory disorder following traumatic brain injury: a pilot study.
Topics: Adult; Analysis of Variance; Brain Injuries; Cholinesterase Inhibitors; Chronic Disease; Donepezil; | 2003 |
Donepezil in a chronic drug user--a potential treatment?
Topics: Adult; Amphetamine-Related Disorders; Attention; Cholinesterase Inhibitors; Donepezil; Dose-Response | 2003 |
Donepezil-induced improvement in delayed matching accuracy by young and old rhesus monkeys.
Topics: Age Factors; Aging; Animals; Cognition; Cognition Disorders; Donepezil; Dose-Response Relationship, | 2004 |
Donepezil for memory impairment in multiple sclerosis.
Topics: Cholinesterase Inhibitors; Donepezil; Humans; Indans; Memory Disorders; Multiple Sclerosis; Piperidi | 2005 |
Acetylcholinesterase inhibitors ameliorate behavioral deficits in the Tg2576 mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Behavior, Animal; Cholinesterase Inhibit | 2005 |
Effect of donepezil and lercanidipine on memory impairment induced by intracerebroventricular streptozotocin in rats.
Topics: Animals; Avoidance Learning; Brain; Calcium Channel Blockers; Cerebral Ventricles; Choline O-Acetylt | 2005 |
Effects of memantine and donepezil on amyloid beta-induced memory impairment in a delayed-matching to position task in rats.
Topics: Amyloid beta-Peptides; Animals; Cholinesterase Inhibitors; Conditioning, Operant; Donepezil; Drug Ad | 2005 |
Donepezil improved memory in multiple sclerosis in a randomized clinical trial.
Topics: Artifacts; Cholinergic Antagonists; Cholinesterase Inhibitors; Donepezil; Drug Interactions; Humans; | 2005 |
Effects of selegiline alone or with donepezil on memory impairment in rats.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Aziridines; Behavior, Animal; Choline; Cholines | 2005 |
Effects of histamine H(3) antagonists and donepezil on learning and mnemonic deficits induced by pentylenetetrazol kindling in weanling mice.
Topics: Animals; Avoidance Learning; Convulsants; Donepezil; Electric Stimulation; Female; Histamine Antagon | 2006 |
Effects of galantamine and donepezil on active and passive avoidance tests in rats with induced hypoxia.
Topics: Animals; Avoidance Learning; Cholinesterase Inhibitors; Disease Models, Animal; Donepezil; Dose-Resp | 2006 |
Mayo Clinic office visit. Mild cognitive impairment. An interview with Ronald Petersen, M.D., Ph.D.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Donepezil; Humans; Indans; Memory Disorders; Nootropic A | 2006 |
Ginkgo biloba extract improves spatial memory in rats mainly but not exclusively via a histaminergic mechanism.
Topics: Acetylcholine; Animals; Brain; Brain Chemistry; Diphenhydramine; Donepezil; Ginkgo biloba; Histamine | 2007 |
Impairment of nonverbal recognition in Alzheimer disease: a PET O-15 study.
Topics: Adaptation, Physiological; Aged; Alzheimer Disease; Brain Mapping; Cerebrovascular Circulation; Chol | 2007 |
Effect of histamine on muscimol-induced working memory deficits in radial maze performance.
Topics: Animals; Brain Chemistry; Cholinesterase Inhibitors; Donepezil; Dose-Response Relationship, Drug; GA | 2007 |
Participation of cholinergic system in memory deficits induced by blockade of hippocampal mGlu(1) receptors.
Topics: Animals; Cholinergic Agents; Cholinergic Antagonists; Cholinesterase Inhibitors; Donepezil; Dose-Res | 2007 |
Is donepezil useful for improving cognitive dysfunction in bipolar disorder?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bipolar Disorder; Cholinesterase Inhibitors; Cognition D | 2008 |
Prucalopride and donepezil act synergistically to reverse scopolamine-induced memory deficit in C57Bl/6j mice.
Topics: Amyloid beta-Protein Precursor; Analysis of Variance; Aniline Compounds; Animals; Benzofurans; Cereb | 2008 |
Spatial memory impairment without apoptosis induced by the combination of beta-amyloid oligomers and cerebral ischemia is related to decreased acetylcholine release in rats.
Topics: Acetylcholine; Amyloid beta-Peptides; Animals; Apoptosis; Behavior, Animal; Brain Ischemia; Cholines | 2008 |
Chronic pentylenetetrazole but not donepezil treatment rescues spatial cognition in Ts65Dn mice, a model for Down syndrome.
Topics: Acetylcholine; Animals; Brain; Cholinesterase Inhibitors; Cognition Disorders; Dementia; Disease Mod | 2008 |
Effect of donepezil and tacrine on oxidative stress in intracerebral streptozotocin-induced model of dementia in mice.
Topics: Acetylcholinesterase; Animals; Avoidance Learning; Brain; Dementia; Disease Models, Animal; Donepezi | 2008 |
Donepezil-induced jaw tremor.
Topics: Aged; Donepezil; Female; Humans; Indans; Jaw; Memory Disorders; Neuropsychological Tests; Nootropic | 2008 |
Exploitation of HIV protease inhibitor Indinavir as a memory restorative agent in experimental dementia.
Topics: Acetylcholinesterase; Animals; Antibiotics, Antineoplastic; Brain; Celecoxib; Cyclooxygenase Inhibit | 2008 |
Neuroprotective and antiamnesic effect of donepezil, a nicotinic acetylcholine-receptor activator, on rats with concussive mild traumatic brain injury.
Topics: Animals; Brain; Brain Concussion; Brain Injuries; Cholinesterase Inhibitors; Disease Models, Animal; | 2008 |
Donepezil medicated memory improvement in traumatic brain injury during post acute rehabilitation.
Topics: Adult; Alzheimer Disease; Brain Injuries; Cholinesterase Inhibitors; Cognitive Behavioral Therapy; D | 1998 |
Relation between cholinesterase inhibitor and Pisa syndrome.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Donepezil; Dopamine Antagonists; Dys | 2000 |
Reversal of scopolamine-induced spatial memory deficits in rats by TAK-147.
Topics: Animals; Benzazepines; Cholinesterase Inhibitors; Donepezil; Indans; Male; Maze Learning; Memory Dis | 2002 |
Donepezil reverses a mnemonic deficit produced by scopolamine but not by perforant path lesion or transient cerebral ischaemia.
Topics: Alzheimer Disease; Animals; Brain Infarction; Brain Ischemia; Cell Death; Cholinesterase Inhibitors; | 2002 |